GLOBAL PHARMA SCREEN FOR TOP PICK
We recommend MRK and Roche as our Top pick from Global pharma space. NVS as well is interesting, trading at defensive valuations, but except for deconsolidation, there are no major triggers that could revive shareholder optimism. It is uncertain, whether NVS management would opt for Deconsolidation, but in case they do one could see up to 30-40% upside from current levels. Our screening criteria is based on: Expected News flow from Pipeline and Potential NPV impact in next 12-18 months
COMPANIES MENTIONED
Merck, Roche, Novartis
Merck, Roche, Novartis
More Publications
SUN PHARMA - A structural improvement at play
US$ 140.00
November 2011
7 pages
SUN PHARMA - Strong Base Business; Protonix Liability Not A Major Concern
US$ 140.00
February 2012
6 pages
SUN PHARMA: Strong Quarter and Brighter Outlook
US$ 140.00
May 2012
7 pages
Outlook 2012 - Japanese Pharma - Cautious Ideas to Seize Value in Happening 2012!
US$ 2,000.00
December 2011
78 pages
SUN PHARMA - At a Sweet Spot
US$ 140.00
August 2012
6 pages
